Federal health regulators took a significant step toward expanding the nation’s influenza prevention toolkit on Friday after an independent advisory panel unanimously endorsed Moderna’s experimental mRNA flu vaccine.
The Vaccines and Related Biological Products Advisory Committee—commonly called VRBPAC—concluded a full-day review session with a 9–0 vote in favor of approving mRNA-1010, Moderna’s seasonal influenza vaccine branded as mFlusiva. The committee, composed of external medical and scientific experts, evaluated extensive clinical trial results and FDA analyses before reaching its consensus.
A rare internal disagreement at the agency briefly threatened to derail the review process. A Trump administration appointee at the FDA had initially attempted to block the vaccine from entering the formal review stage, citing procedural concerns. However, career scientists within the FDA conducted their own evaluation and presented supportive findings to the advisory panel, paving the way for Friday’s vote.
The decision was grounded in two major clinical studies. A Phase 3 trial involving more than 40,000 adults aged 50 and older showed that the mRNA vaccine reduced the risk of laboratory-confirmed influenza by approximately 27 percent compared to standard flu shots. In a separate Phase 3 study of nearly 3,000 adults aged 65 and older, the vaccine generated stronger immune responses than high-dose flu vaccines, which are currently recommended for this high-risk group. Across both trials, the vaccine demonstrated a favorable safety profile with no major red flags.
VRBPAC members emphasized the potential public health benefits of adding an mRNA-based option to the seasonal flu vaccination strategy. “The data suggest this vaccine could offer meaningful protection, especially in older adults who face higher complications from influenza,” said one committee member during the public discussion.
Moderna plans to seek full FDA approval for mFlusiva, which would make it the first mRNA-based seasonal flu vaccine available in the United States. If authorized, it would join a limited arsenal of flu vaccines that already includes standard-dose, high-dose, adjuvanted, and recombinant options.
The FDA is expected to make a final decision in the coming months, though it typically follows the recommendations of its advisory committees. With flu season approaching and vaccine effectiveness waning in vulnerable populations, the potential approval of an mRNA flu vaccine could represent a turning point in how seasonal influenza is prevented in the years ahead.
AI summary
FDA’nın danışma kurulu, Moderna’nın mRNA grip aşısını oybirliğiyle onayladı. Peki bu yenilikçi aşı ne kadar etkili ve gelecekteki grip sezonlarında neler değişecek? Tüm detaylar burada.
